F. Dehout

Prevalence of uncontrolled hypertension in patients with Fabry disease.

G. Houge, A. Mehta, A. Schwarting, 2006, American journal of hypertension.

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

A. Mehta, A. Linhart, G. Sunder-Plassmann, 2004, European journal of clinical investigation.

B-cell response to a standardized breakfast in end-stage renal failure

J. Meunier, P. Lefèbvre, J. Daubresse, 2007, Acta diabetologia latina.

Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration rate in patients with Fabry disease: preliminary data

A. Mehta, A. Schwarting, M. Beck, 2003, Acta paediatrica (Oslo, Norway : 1992). Supplement.

Fabry disease: overall effects of agalsidase alfa treatment

G. Houge, A. Mehta, U. Ramaswami, 2004, European journal of clinical investigation.

Enzyme replacement therapy and renal function in 201 patients with Fabry disease.

S. Feriozzi, A. Mehta, A. Schwarting, 2006, Clinical nephrology.

ACE inhibitors and anaphylactoid reactions to high-flux membrane dialysis

P. Aljama, A. Martín-Malo, C. Tielemans, 1991, The Lancet.

Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease

L. Van Maldergem, F. Dehout, D. Roland, 2004, Journal of Inherited Metabolic Disease.

Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey.

G. Houge, A. Mehta, A. Schwarting, 2005, Kidney international.

Kidney graft dysfunction after drug interaction between miocamycin and cyclosporin

D. Abramowicz, F. Dehout, S. Treille, 1999, Transplant international : official journal of the European Society for Organ Transplantation.